Michael Gallagher - Allergan Plc Lead Independent Director

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>AP</div>
AGN -- USA Stock  

Earnings Report: 4th of August 2020  

  Director
Dr. Michael R. Gallagher is an Independent Director of Allergan Plc. Mr. Gallagher joined the Board of Directors in March 2015. He previously served on the Allergan, Inc. Board of Directors from 1998 until our acquisition of Allergan, Inc. In 2004, Mr. Gallagher retired as Chief Executive Officer and as a Director of Playtex Products, Inc. Prior to joining Playtex in 1995, Mr. Gallagher was Chief Executive Officer of North America for Reckitt Colman plc President and Chief Executive Officer of Eastman Kodaks subsidiary, LF Products President of the Lehn Fink Consumer Products Division at Sterling Drug, General Manager of the Household Products Division of the Clorox Company, and Brand Manager of The Procter Gamble Company
Age: 69  Director Since 2015      
862 261 7000  http://www.allergan.com
Gallagher is a member and past Chairman of the Board of Advisors of the Haas School of Business, University of California, Berkeley. The Board of Directors has concluded that, with more than three decades of experience in key leadership roles at public and private personal care and consumer products companies, including as the former Chief Executive Officer of Playtex Products, Mr. Gallagher provides our Board of Directors with a wealth of business and management experience, as well as invaluable broadbased personal care and consumer products experience and therefore should serve on the Board of Directors.

Michael Gallagher Latest Insider Activity

Allergan Plc Management Efficiency

Allergan Plc has Return on Asset of (0.0564) % which means that on every $100 spent on asset it lost $0.0564. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (0.0913) %, meaning that it generated no profit with money invested by stockholders. Allergan Plc management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.
The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has a current ratio of 0.98, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Laurie BrlasPerrigo Company Plc
2016
Linda RhodesZoetis Inc
2017
William SteereZoetis Inc
2013
Ashok GangulyDr Reddys Laboratories
2009
Jeffrey KindlerPerrigo Company Plc
2017
J MoreauDr Reddys Laboratories
2007
Michael JandernoaPerrigo Company Plc
2007
Frances FergussonPfizer Inc
2009
Wyllie CornwellPfizer Inc
1997
Allan ObermanDr Reddys Laboratories
2019
Anupam PuriDr Reddys Laboratories
2002
Herman MorrisPerrigo Company Plc
1999
Bharat DoshiDr Reddys Laboratories
2016
David AltshulerVertex Pharmaceuticals Incorpor
2015
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Jeffrey SmithPerrigo Company Plc
2017
Susan HockfieldPfizer Inc
2020
George SingRegeneron Pharmaceuticals
1988
Alan GarberVertex Pharmaceuticals Incorpor
2017
Joseph GoldsteinRegeneron Pharmaceuticals
1991
Donal OConnorPerrigo Company Plc
2014

Company Summary

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc. Allergan Plc operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 17400 people.Allergan Plc (AGN) is traded on New York Stock Exchange in USA and employs 17,400 people.

Allergan Plc Leadership Team

Matthew Walsh, Chief Financial Officer, Executive Vice President
Robert Bailey, Chief Legal Officer and Corporate Secretary
Robert Stewart, Executive VP and President of Generic and Global Operations
Ronald Taylor, Independent Director
Adriane Brown, Independent Director
William Meury, Executive Vice President, Chief Commercial Officer
Brenton Saunders, Chairman of the Board, President, Chief Executive Officer
Wayne Swanton, Executive Vice President - Global Operations
Robert Hugin, Independent Director
Nicholson, Chief R&D Officer
Christopher Bodine, Independent Director
Karen Ling, Chief Human Resource Officer, Executive Vice President
Michael Gallagher, Lead Independent Director
Paul Bisaro, Executive Chairman
Thomas Freyman, Independent Director
Catherine Klema, Lead Independent Director
James DArecca, Chief Accounting Officer
Christopher Coughlin, Lead Independent Director
Nesli Basgoz, Independent Director
Philippe Schaison, Executive Vice President and President Allergan Medical
Maria Hilado, CFO and Executive VP
Joseph Boccuzi, Independent Director
Patrick OSullivan, Independent Director
Fred Weiss, Independent Director
A Bailey, Executive Vice President, Chief Legal Officer and Corporate Secretary
Alex Kelly, Chief Communications Officer
CDavid Nicholson, Executive Vice President, Chief R&D Officer
Carol Davidson, Independent Director
Michael Greenberg, Independent Director
Ron Taylor, Independent Director
Jonathon Kellerman, Executive Vice President Chief Compliance Officer
Paul Navarre, Executive Vice President and President International Brands
James Bloem, Independent Director
Karina Calzadilla, IR Contact Officer
Peter McDonnell, Independent Director

Stock Performance Indicators

Current Sentiment - AGN

Allergan Plc Investor Sentiment

Predominant part of Macroaxis users are presently bullish on Allergan Plc. What is your sentiment towards investing in Allergan Plc? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Allergan Plc Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Allergan Plc and Pfizer Inc. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page